FR14C0019I1 - - Google Patents

Info

Publication number
FR14C0019I1
FR14C0019I1 FR14C0019C FR14C0019I1 FR 14C0019 I1 FR14C0019 I1 FR 14C0019I1 FR 14C0019 C FR14C0019 C FR 14C0019C FR 14C0019 I1 FR14C0019 I1 FR 14C0019I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26781018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0019(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR14C0019I1 publication Critical patent/FR14C0019I1/fr
Application granted granted Critical
Publication of FR14C0019I2 publication Critical patent/FR14C0019I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR14C0019C 1998-06-19 2014-03-07 COMPOSES DE PYRROLO 2,3d]PYRIMIDINE Active FR14C0019I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8986698P 1998-06-19 1998-06-19
US10478798P 1998-10-19 1998-10-19
PCT/IB1999/001100 WO1999065908A1 (en) 1998-06-19 1999-06-14 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS

Publications (2)

Publication Number Publication Date
FR14C0019I1 true FR14C0019I1 (sl) 2014-04-11
FR14C0019I2 FR14C0019I2 (fr) 2015-01-02

Family

ID=26781018

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0019C Active FR14C0019I2 (fr) 1998-06-19 2014-03-07 COMPOSES DE PYRROLO 2,3d]PYRIMIDINE

Country Status (41)

Country Link
US (3) US6610847B2 (sl)
EP (1) EP1087970B1 (sl)
JP (3) JP4666762B2 (sl)
KR (1) KR100415791B1 (sl)
CN (1) CN1128800C (sl)
AP (1) AP1021A (sl)
AR (1) AR016499A1 (sl)
AT (1) ATE265458T1 (sl)
AU (1) AU3951899A (sl)
BG (1) BG65119B1 (sl)
BR (1) BR9911365A (sl)
CA (1) CA2335492C (sl)
CZ (1) CZ20004727A3 (sl)
DE (1) DE69916833T2 (sl)
DK (1) DK1087970T3 (sl)
EA (1) EA005852B1 (sl)
ES (1) ES2219018T3 (sl)
FR (1) FR14C0019I2 (sl)
GE (1) GEP20074227B (sl)
GT (1) GT199900090A (sl)
HK (1) HK1036801A1 (sl)
HR (1) HRP20000885B1 (sl)
HU (1) HUP0102574A3 (sl)
ID (1) ID26698A (sl)
IL (1) IL139586A0 (sl)
MA (1) MA26654A1 (sl)
MY (1) MY125916A (sl)
NO (2) NO318784B1 (sl)
NZ (1) NZ518444A (sl)
OA (1) OA11572A (sl)
PA (1) PA8476001A1 (sl)
PE (1) PE20000698A1 (sl)
PL (1) PL198640B1 (sl)
PT (1) PT1087970E (sl)
RS (1) RS50087B (sl)
SA (1) SA99200283B1 (sl)
SK (1) SK286640B6 (sl)
TN (1) TNSN99126A1 (sl)
TR (1) TR200003719T2 (sl)
TW (1) TW505646B (sl)
WO (1) WO1999065908A1 (sl)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50087B (sr) * 1998-06-19 2009-01-22 Pfizer Products Inc., Pirolo (2,3-d) pirimidin jedinjenja
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
PT1235830E (pt) * 1999-12-10 2004-04-30 Pfizer Prod Inc Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases
SI1294724T1 (sl) * 2000-06-26 2006-08-31 Pfizer Prod Inc Pirolo(2,3-d)primidinske spojine kot imunosupresivna sredstva
JP2004509876A (ja) 2000-09-20 2004-04-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ４−アミノ−キナゾリン
US7067550B2 (en) * 2000-11-03 2006-06-27 Massachusetts Institute Of Technology Treatments for neurotoxicity in Alzheimer's Disease
DE10063294A1 (de) * 2000-12-19 2002-07-04 Aventis Pharma Gmbh Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
ATE305303T1 (de) 2001-02-12 2005-10-15 Hoffmann La Roche 6-substituierte pyridopyrimidine
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0115393D0 (en) * 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
DE60216281T2 (de) 2001-06-29 2007-07-05 Ab Science Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
CA2452368A1 (en) 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
EP1401416B1 (en) * 2001-06-29 2006-10-25 AB Science Use of c-kit inhibitors for treating inflammatory bowel diseases (ibd)
DE60227709D1 (de) * 2001-06-29 2008-08-28 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
CA2452169A1 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
DE60320933D1 (de) * 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
JP4423043B2 (ja) 2002-01-23 2010-03-03 バイエル ファーマセチカル コーポレーション Ｒｈｏ−キナーゼ阻害剤
US6924290B2 (en) 2002-01-23 2005-08-02 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
EP1388541A1 (en) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
CA2507392A1 (en) 2002-11-26 2004-06-10 Pfizer Products Inc. Method of treatment of transplant rejection
WO2005044835A1 (en) * 2003-10-27 2005-05-19 Genelabs Technologies, Inc. METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
EP1689407A1 (en) * 2003-11-25 2006-08-16 Pfizer Products Inc. Method of treatment of atherosclerosis
NZ549673A (en) * 2004-03-30 2010-03-26 Taisho Pharmaceutical Co Ltd Pyrimidine derivatives and methods of treatment related to the use thereof
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US7358250B2 (en) 2004-06-29 2008-04-15 Amgen Inc. Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity
TW200615268A (en) 2004-08-02 2006-05-16 Osi Pharm Inc Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
EP1891066B1 (en) 2005-05-13 2010-12-22 Irm, Llc Compounds and compositions as protein kinase inhibitors
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
US8163767B2 (en) 2005-07-14 2012-04-24 Astellas Pharma Inc. Heterocyclic Janus Kinase 3 inhibitors
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
CN101801971A (zh) * 2005-09-30 2010-08-11 沃泰克斯药物股份有限公司 可用作janus激酶抑制剂的脱氮嘌呤
ES2970354T3 (es) 2005-12-13 2024-05-28 Incyte Holdings Corp Derivados de pirrolo[2,3-d]pirimidina como inhibidores de Janus quinasas
CN101460161A (zh) * 2006-03-29 2009-06-17 弗尔德里克斯制药股份有限公司 α-突触核蛋白毒性的抑制
EP3719018A1 (en) 2006-04-25 2020-10-07 Astex Therapeutics Ltd Purine and deazapurine derivatives as pharmaceutical compounds
CA2673038C (en) 2006-12-22 2015-12-15 Incyte Corporation Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
JP5287253B2 (ja) 2007-01-12 2013-09-11 アステラス製薬株式会社 縮合ピリジン化合物
WO2008119792A1 (en) * 2007-04-02 2008-10-09 Palau Pharma, S. A. Pyrrolopyrimidine derivatives as jak3 inhibitors
TR201903488T4 (tr) 2007-06-13 2019-04-22 Incyte Holdings Corp Janus kinaz inhibitörü (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-siklopentilpropannitril tuzlarının kullanımı.
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
DE102007027800A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
BRPI0817402A2 (pt) * 2007-11-10 2019-09-24 Landmark Graphics Corp A Halliburton Company dispositivos e métodos para automação de fluxos de trabalho, adaptação e integração
EP2222162B1 (en) * 2007-11-28 2016-11-16 Dana-Farber Cancer Institute, Inc. Small molecule myristate inhibitors of bcr-abl and methods of use
CN101981036B (zh) 2008-02-06 2013-09-04 诺瓦提斯公司 吡咯并[2,3-d]嘧啶及其作为酪氨酸激酶抑制剂的用途
CA2713710A1 (en) * 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
RS55263B1 (sr) 2008-03-11 2017-02-28 Incyte Holdings Corp Derivati azetidina i ciklobutana kao jak inhibitori
WO2009115084A2 (de) * 2008-03-20 2009-09-24 Schebo Biotech Ag Neue pyrrolopyrimidin-derivate und deren verwendungen
EP2320895A2 (en) * 2008-07-03 2011-05-18 Exelixis, Inc. Cdk modulators
KR20110050654A (ko) * 2008-08-01 2011-05-16 바이오크리스트 파마수티컬즈, 인코퍼레이티드 Ｊａｋ3 억제제로서의 피페리딘 유도체
BRPI0917459B1 (pt) 2008-08-20 2017-09-12 Zoetis Services Llc N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
US8385364B2 (en) * 2008-09-24 2013-02-26 Nec Laboratories America, Inc. Distributed message-passing based resource allocation in wireless systems
CA2759026C (en) 2009-04-20 2019-01-15 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of janus kinase 3
TWI484962B (zh) 2009-05-22 2015-05-21 Incyte Corp 作為ｊａｋ抑制劑之３－〔４－（７ｈ－吡咯并〔２，３－ｄ〕嘧啶－４－基）－１ｈ－吡唑－１－基〕辛烷或庚腈
KR101771401B1 (ko) 2009-05-22 2017-08-25 인사이트 홀딩스 코포레이션 야누스 키나제 억제제로서 피라졸­４­일­피롤로［２,３­ｄ］피리미딘 및 피롤­３­일­피롤로［２,３­ｄ］피리미딘의 Ｎ­(헤테로)아릴­피롤리딘 유도체
CN102574857B (zh) * 2009-07-08 2015-06-10 利奥制药有限公司 作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EA021478B1 (ru) 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
CA2776028C (en) * 2009-10-15 2015-12-01 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
JP5739446B2 (ja) * 2009-12-18 2015-06-24 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
WO2011097087A1 (en) 2010-02-05 2011-08-11 Pfizer Inc. Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors
EP2360158A1 (en) * 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
DK2545045T3 (en) 2010-03-10 2016-01-25 Incyte Holdings Corp PIPERIDINE-4-YL-azetidine derivatives AS JAK1 INHIBITORS
EP2590981B1 (en) * 2010-07-09 2014-09-03 Leo Pharma A/S Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
RU2013136906A (ru) 2011-01-07 2015-02-20 Лео Фарма А/С Новые производные сульфамидпиперазина в качестве ингибиторов протеинтирозинкиназы и их фармацевтическое применение
PT2675451E (pt) 2011-02-18 2015-10-16 Incyte Corp Terapia de combinação com inibidores mtor/jak
JP6277121B2 (ja) 2011-03-22 2018-02-07 アドヴィナス・セラピューティックス・リミテッド 置換された縮合三環式化合物、その組成物および医学的応用
EP2710006A1 (en) * 2011-05-17 2014-03-26 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
MX344479B (es) 2011-06-20 2016-12-16 Incyte Holdings Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de cinasa janus (jak).
CA2844507A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag Jak pi3k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AU2012345732B2 (en) * 2011-11-30 2016-07-14 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
CA2857977C (en) * 2011-12-21 2020-10-20 Jiangsu Hengrui Medicine Co., Ltd. Pyrrole six-membered heteroaryl ring derivative, preparation method thereof, and medicinal uses thereof
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
CA2873967A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
AP3902A (en) * 2012-06-29 2016-11-17 Pfizer Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
TWI574946B (zh) * 2012-07-17 2017-03-21 葛蘭素史密斯克藍智慧財產權有限公司 化合物
EP2874630B1 (en) * 2012-07-20 2018-12-05 Zoetis Services LLC Dosing regimen for janus kinase (jak) inhibitors
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
JP2015529242A (ja) 2012-09-21 2015-10-05 アドヴィヌス セラピューティクス リミテッドＡｄｖｉｎｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 置換された縮合三環式化合物、組成物およびその医薬用途
CN102936251A (zh) * 2012-11-05 2013-02-20 上海毕得医药科技有限公司 一种吡咯并[2,3-d]嘧啶衍生物的制备方法
KR20210037012A (ko) 2012-11-15 2021-04-05 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
KR101683061B1 (ko) * 2013-02-07 2016-12-07 한국과학기술연구원 ＪＡＫ-3 저해제로 유용한 ７Ｈ-피롤로[2,3-ｄ]피리미딘-4-싸이올 유도체
MY177476A (en) 2013-02-22 2020-09-16 Pfizer Pyrrolo [2,3-d]pyrimidine derivatives as inhibitors of janus kinases (jak)
CA2903418C (en) 2013-03-06 2021-03-23 Incyte Corporation Processes and intermediates for making a jak inhibitor
EP2970119B1 (en) * 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
BR122020001831A8 (pt) 2013-08-07 2023-01-24 Incyte Corp {1-{1-[3-flúor-2-(trifluormetil)isonicotinol]piperidin-4-il}-3-[4-(7h-pirrolo[2,3-d]primidin-4-il) -1h-pirazol-1-il]azetidin-3-il}acetonitrila, seu uso, formas de dosagem de liberação sustentada e doses
CN106061973B (zh) 2013-12-05 2019-07-09 辉瑞公司 吡咯并[2,3-d]嘧啶基、吡咯并[2,3-b]吡嗪基和吡咯并[2,3-d]吡啶基丙烯酰胺
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体
CA2984183C (en) 2015-05-01 2021-11-09 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
MX2017013797A (es) * 2015-05-29 2018-03-21 Wuxi Fortune Pharmaceutical Co Ltd Inhibidor de janus quinasa.
KR101771219B1 (ko) * 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
JP6873980B2 (ja) 2015-09-14 2021-05-19 ファイザー・インク ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
CN106831779B (zh) * 2015-11-28 2019-07-19 南昌弘益药业有限公司 一类jak激酶抑制剂的新化合物
BR112018016708B1 (pt) 2016-02-16 2023-11-07 Zoetis Services Llc Compostos de 7h-pirrolo[2,3-d]pirimidina e processo para preparar os ditos compostos
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
AU2017376398B2 (en) 2016-12-14 2021-07-15 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
JP6944496B2 (ja) 2018-10-22 2021-10-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
CN113272306A (zh) * 2018-11-05 2021-08-17 爱维斯塔制药解决方案有限公司 化学化合物
EP3906029A4 (en) 2018-12-31 2022-09-21 Biomea Fusion, LLC INHIBITORS OF MENIN-MLL INTERACTION
US11084825B2 (en) 2018-12-31 2021-08-10 Biomea Fusion, Llc Substituted pyridines as irreversible inhibitors of menin-MLL interaction
WO2020198583A1 (en) 2019-03-27 2020-10-01 Insilico Medicine Ip Limited Bicyclic jak inhibitors and uses thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
AU2021401834A1 (en) 2020-12-18 2023-07-06 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
MX2024002189A (es) 2021-08-20 2024-06-11 Biomea Fusion Inc Forma cristalina de n-[4-[4-(4-morfolinil)-7h-pirrolo[2,3-d]pirimi din-6-il]fenil]-4-[[3(r)-[(1-oxo)-2-propen-1-il)amino]-1-piperidi nil]metil]-2-piridinacarboxamida, un inhibidor irreversible de menina-mll para el tratamiento del cancer.
WO2023029943A1 (zh) * 2021-09-03 2023-03-09 星药科技(北京)有限公司 一种芳杂环化合物及其制备方法和用途
WO2023055731A1 (en) * 2021-09-28 2023-04-06 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
CA3242449A1 (en) 2021-12-24 2023-06-29 Intervet International B.V. Use of aminopyrazole compounds
GB202215132D0 (en) * 2022-10-13 2022-11-30 Norwegian Univ Sci & Tech Ntnu Compound
GB202215117D0 (en) * 2022-10-13 2022-11-30 Norwegian Univ Sci & Tech Ntnu Compound

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB915303A (en) 1958-03-13 1963-01-09 Wellcome Found Pyrrolo[2,3-d]pyrimidine derivatives and the manufacture thereof
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
EP0682027B1 (de) * 1994-05-03 1997-10-15 Novartis AG Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
DE69531558T2 (de) * 1995-06-07 2004-03-18 Pfizer Inc. Heterocyclische kondensierte pyrimidin-derivate
EP0836602B1 (en) 1995-07-05 2002-01-30 E.I. Du Pont De Nemours And Company Fungicidal pyrimidinones
PT836605E (pt) * 1995-07-06 2002-07-31 Novartis Ag Pirrolopirimidinas e processos para a sua preparacao
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
CN1168138A (zh) 1995-11-14 1997-12-17 法玛西雅厄普约翰公司 芳基和杂芳基嘌呤化合物
DE69712745T2 (de) 1996-01-23 2002-10-31 Novartis Ag, Basel Pyrrolopyrimidinen und verfahren zu deren herstellung
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU1794697A (en) 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
DE69718472T2 (de) 1996-07-13 2003-11-06 Glaxo Group Ltd., Greenford Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
DK0938486T3 (da) 1996-08-23 2008-07-07 Novartis Ag Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
AU4718997A (en) * 1996-11-27 1998-06-22 Pfizer Inc. Fused bicyclic pyrimidine derivatives
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
US6187552B1 (en) 1997-03-24 2001-02-13 Pharmacia & Upjohn Company Method for identifying inhibitors of JAK2/cytokine receptor binding
US6080847A (en) * 1997-12-04 2000-06-27 Incyte Pharmaceuticals, Inc. Proteins associated with cell proliferation
AU3378799A (en) 1998-04-02 1999-10-25 Neurogen Corporation Aminoalkyl substituted pyrrolo(2,3-b)pyridine and pyrrolo(2,3-d)pyrimidine derivatives: modulators of crf1 receptors
CA2333392A1 (en) 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
RS50087B (sr) * 1998-06-19 2009-01-22 Pfizer Products Inc., Pirolo (2,3-d) pirimidin jedinjenja
JP2004504259A (ja) 1998-06-30 2004-02-12 パーカー　ヒューズ　インスティテュート Ｊａｋ−３インヒビターを用いたｃ−ｊｕｎ発現の阻害方法
MXPA01001893A (es) 1998-08-21 2002-04-24 Parker Hughes Inst Derivados de quinazolina.
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
PT1235830E (pt) * 1999-12-10 2004-04-30 Pfizer Prod Inc Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases
SI1294724T1 (sl) * 2000-06-26 2006-08-31 Pfizer Prod Inc Pirolo(2,3-d)primidinske spojine kot imunosupresivna sredstva
AU2009100870A4 (en) 2008-10-01 2009-10-22 Rock Tone Enterprise Co., Ltd. Drive mechanism for dehydrator
TWM358618U (en) 2008-12-26 2009-06-11 Rock Tone Entpr Co Ltd Combination structure of mop holder and cleaning body

Also Published As

Publication number Publication date
HK1036801A1 (en) 2002-01-18
WO1999065908A1 (en) 1999-12-23
KR100415791B1 (ko) 2004-01-24
CA2335492C (en) 2005-05-17
HRP20000885A2 (en) 2001-10-31
BR9911365A (pt) 2001-03-13
US6610847B2 (en) 2003-08-26
NZ518444A (en) 2004-04-30
IL139586A0 (en) 2002-02-10
YU78500A (sh) 2003-04-30
PL345123A1 (en) 2001-12-03
NO2014012I1 (no) 2014-06-02
ATE265458T1 (de) 2004-05-15
RS50087B (sr) 2009-01-22
PL198640B1 (pl) 2008-07-31
US20020019526A1 (en) 2002-02-14
PE20000698A1 (es) 2000-08-19
HUP0102574A3 (en) 2002-01-28
AP9901584A0 (en) 1999-06-30
TNSN99126A1 (fr) 2005-11-10
CN1305480A (zh) 2001-07-25
HUP0102574A2 (hu) 2001-11-28
TW505646B (en) 2002-10-11
CA2335492A1 (en) 1999-12-23
US7687507B2 (en) 2010-03-30
US6890929B2 (en) 2005-05-10
SK18982000A3 (sk) 2002-08-06
EA200001203A1 (ru) 2001-06-25
PT1087970E (pt) 2004-06-30
HRP20000885B1 (en) 2007-03-31
NO20006453D0 (no) 2000-12-18
CN1128800C (zh) 2003-11-26
AU3951899A (en) 2000-01-05
GT199900090A (es) 2000-12-09
JP2012041365A (ja) 2012-03-01
AR016499A1 (es) 2001-07-04
US20030212273A1 (en) 2003-11-13
BG65119B1 (bg) 2007-03-30
EA005852B1 (ru) 2005-06-30
ES2219018T3 (es) 2004-11-16
MA26654A1 (fr) 2004-12-20
CZ20004727A3 (cs) 2002-03-13
AP1021A (en) 2001-11-09
SK286640B6 (sk) 2009-03-05
OA11572A (en) 2004-07-01
JP2002518393A (ja) 2002-06-25
NO20006453L (no) 2001-02-05
DK1087970T3 (da) 2004-08-02
GEP20074227B (en) 2007-10-25
SA99200283B1 (ar) 2006-03-25
DE69916833T2 (de) 2005-04-14
US20050171128A1 (en) 2005-08-04
PA8476001A1 (es) 2003-09-05
JP4666762B2 (ja) 2011-04-06
JP2007284455A (ja) 2007-11-01
MY125916A (en) 2006-08-30
ID26698A (id) 2001-02-01
FR14C0019I2 (fr) 2015-01-02
TR200003719T2 (tr) 2001-03-21
KR20010053004A (ko) 2001-06-25
NO318784B1 (no) 2005-05-09
DE69916833D1 (de) 2004-06-03
JP4971068B2 (ja) 2012-07-11
BG105129A (en) 2001-11-30
EP1087970A1 (en) 2001-04-04
EP1087970B1 (en) 2004-04-28

Similar Documents

Publication Publication Date Title
BE2014C048I2 (sl)
FR14C0019I1 (sl)
BE2012C041I2 (sl)
JP2003522318A5 (sl)
JP2001521261A5 (sl)
BE2009C051I2 (sl)
JP2001509620A5 (sl)
BE2011C024I2 (sl)
JP2002542400A5 (sl)
JP2000017102A6 (sl)
JP2002511634A5 (sl)
BRPI9816295A2 (sl)
IN187518B (sl)
JP2590584C (sl)
GB9800219D0 (sl)
IN185068B (sl)
JP2535279C (sl)
JP2540054C (sl)
JP2574583C (sl)
JP2580762C (sl)
CN3074692S (sl)
CN3075297S (sl)
CN3074158S (sl)
CN3074474S (sl)
CN3081497S (sl)